Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.32 USD | -1.30% | -3.78% | -10.14% |
05-10 | Pacira BioSciences Prices $250 Million Convertible Senior Notes Offering | MT |
05-08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.14% | 1.41B | |
+38.69% | 728B | |
+34.28% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+17.02% | 244B | |
+9.31% | 207B | |
-5.07% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q2 Revenue $169.5M, vs. Street Est of $175M